CAM
RLAY icon

Congress Asset Management’s Relay Therapeutics RLAY Stock Holding History

Congress Asset Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.7M Buy
626,141
+7,203
+1% +$105K 0.07% 207
2026
Q1 		$6.16M Buy
618,938
+204,771
+49% +$1.83M 0.04% 240
2025
Q4 		$3.5M Buy
414,167
+5,325
+1% +$38K 0.02% 251
2025
Q3 		$2.13M Buy
408,842
+252,142
+161% +$961K 0.01% 278
2025
Q2 		$542K Buy
156,700
+498
+0.3% +$1.48K ﹤0.01% 339
2025
Q1 		$409K Sell
156,202
-1,283
-0.8% -$5.03K ﹤0.01% 334
2024
Q4 		$649K Buy
157,485
+11,061
+8% +$60.2K ﹤0.01% 335
2024
Q3 		$1.04M Sell
146,424
-1,186
-0.8% -$8.86K 0.01% 298
2024
Q2 		$962K Sell
147,610
-1,472
-1% -$10.1K 0.01% 299
2024
Q1 		$1.24M Buy
149,082
+2,108
+1% +$20.6K 0.01% 292
2023
Q4 		$1.62M Buy
146,974
+540
+0.4% +$4.56K 0.01% 302
2023
Q3 		$1.23M Buy
146,434
+207
+0.1% +$2.23K 0.01% 298
2023
Q2 		$1.84M Buy
+146,227
New +$1.82M 0.02% 287

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Congress Asset Management's RLAY Position: Q2 2026 in Review

Congress Asset Management increased its Relay Therapeutics (RLAY) stake by 1.2% in Q2 2026, buying an estimated $105K and bringing the position to 626,141 shares worth $11.7M. The position accounts for 0.07% of the portfolio, ranked #207.

Congress Asset Management first reported a position in RLAY in Q2 2023 and has held it in 13 quarters since. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Congress Asset Management held 626,141 shares of Relay Therapeutics worth $11.7M as of Q2 2026.
  • Congress Asset Management bought 7,203 Relay Therapeutics shares in Q2 2026, an estimated $105K.
  • Relay Therapeutics made up 0.07% of Congress Asset Management's portfolio in Q2 2026, its #207 holding.
  • Congress Asset Management first reported a position in Relay Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Congress Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.